CoChat

Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma

Open access
Sommer, Cesar, Boldajipour, Bijan, Kuo, Tracy C., Bentley, Trevor, Sutton, Janette, Chen, Amy, Geng, Tao, Dong, Holly, Galetto, Roman, Valton, Julien, Pertel, Thomas, Juillerat, Alexandre, Gariboldi, Annabelle, Pascua, Edward, Brown, Colleen, Chin, Sherman M., Sai, Tao, Ni, Yajin, Duchateau, Philippe, Smith, Julianne, Rajpal, Arvind, Van Blarcom, Thomas, Chaparro-Riggers, Javier, Sasu, Barbra J. · 2019 · Molecular Therapy
Cited by 151

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Clinical success of autologous CD19-directed chimeric antigen receptor T cells (CAR Ts) in acute lymphoblastic leukemia and non-Hodgkin lymphoma suggests that CAR Ts may be a promising therapy for hematological malignancies, including multiple myeloma. However, autologous CAR T therapies have limitations that may impact clinical use, including lengthy vein-to-vein time and manufacturing constraints. Allogeneic CAR T (AlloCAR T) therapies may overcome these innate limitations of autologous CAR T therapies. Unlike autologous cell therapies, AlloCAR T therapies employ healthy donor T cells that are isolated in a manufacturing facility, engineered to express CARs with specificity for a tumor-associated antigen, and modified using gene-editing technology to limit T cell receptor (TCR)-mediated immune responses. Here, transcription activator-like effector nuclease (TALEN) gene editing of B cell maturation antigen (BCMA) CAR Ts was used to confer lymphodepletion resistance and reduced graft-versus-host disease (GvHD) potential. The safety profile of allogeneic BCMA CAR Ts was further enhanced by incorporating a CD20 mimotope-based intra-CAR off switch enabling effective CAR T elimination in the presence of rituximab. Allogeneic BCMA CAR Ts induced sustained antitumor responses in mice supplemented with human cytokines, and, most importantly, maintained their phenotype and potency after scale-up manufacturing. This novel off-the-shelf allogeneic BCMA CAR T product is a promising candidate for clinical evaluation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2019.04.001

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 151

Metadata

Authors
Sommer, C., Boldajipour, B., Kuo, T. C., Bentley, T., Sutton, J., Chen, A., Geng, T., Dong, H., Galetto, R., Valton, J., Pertel, T., Juillerat, A., Gariboldi, A., Pascua, E., Brown, C., Chin, S. M., Sai, T., Ni, Y., Duchateau, P., Smith, J., Rajpal, A., Van Blarcom, T., Chaparro-Riggers, J., & Sasu, B. J.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2019-06
Volume
27
Issue
6
Pages
1126-1138
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2936355201
Cited by
151
References
12
FWCI
7.44
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.